cck 8

Sincalide (CCK-8) 是一种速效的胆囊收缩素的氨基酸多肽激素类似物，可在胆囊造影术中静脉使用。它的肝胆生理作用是增加胆汁的分泌，使胆囊收缩并使 Oddi 的括约肌松弛，从而使胆汁排入十二指肠。它是一种通过注射促进胆囊收缩并帮助诊断胆囊和胰腺疾病的药物。

Homoharringtonine (HHT) 属于生物碱类天然产物，可以抑制蛋白质的翻译，具有细胞毒性。Homoharringtonine 作用于肿瘤细胞的核糖体，抑制蛋白质翻译的延伸步骤，从而抑制蛋白质合成，具有抗肿瘤活性。

Sincalide ammonium (CCK-8 ammonium) 是一种有效的氨基酸多肽激素胆囊收缩素 (CCK) 的类似物，是保留了 CCK 的大部分生物活性的活性片段。Sincalide ammonium 促进胆汁的分泌，使胆囊收缩并使 Oddi 的括约肌松弛，从而促进胆汁排入十二指肠。Sincalide ammonium 可通过注射促进胆囊收缩，常用于辅助诊断胆囊、胰腺疾病和胆囊造影术。

N-Cbz-DL-tryptophan 是一种胆囊收缩素受体拮抗剂，可消除离体心脏对 CCK-8 的反应。

Dexloxiglumide, an active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). It is a selective antagonist of cholecystokinin type A (CCKA) receptors.

ARL 15849XX, a CCK-8 analog, is a novel anti-obesity agent.

Fpl 14294 is a novel CCK-8 agonist with effective intranasal anorectic activity in the rat.

Snf 8906 is a CCK-8 analog.

Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat (ITF2357) suppresses total LPS-induced IL-1β production robustly compared with the reduction by ITF3056. At 25, 50, and 100 nM, Givinostat reduced IL-1β secretion more than 70%. Givinostat (ITF-2357) suppresses the production of IL-6 in PBMCs stimulated with TLR agonists as well as the combination of IL-12 plus IL-18. IL-6 secretion decreases to 50% at 50 nM Givinostat, but at 100 and 200 nM, there is no reduction[1]. As shown by the CCK-8 assay, Givinostat (ITF-2357) inhibits JS-1 cell proliferation in a concentration-dependent manner. Treatment with Givinostat ≥500 nM is associated with significant inhibition of JS-1 cell proliferation (P<0.01). Also, the cell inhibition rate significantly differs between the group cotreated with Givinostat ≥250 nM plus LPS and the group without LPS treatment (same Givinostat concentration) (P<0.05)[2]. Givinostat (ITF2357) at 10 mg kg is used as a positive control and, as expected, reduced serum TNFα by 60%. Strikingly, pretreatment of ITF3056 starting at 0.1 mg kg significantly reduces the circulating TNFα by nearly 90%. To achieve a significant increase in serum IL-1β production, a higher dose of LPS is injected (10 mg kg), and blood is collected after 4 h. Similarly, when pretreated with lower doses of Givinostat (ITF-2357) (1 or 5 mg kg), there is a 22% reduction for 1 mg kg and 40% for 5 mg kg[1]. [1]. Li S, et al. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J Biol Chem. 2015 Jan 23;290(4):2368-78. [2]. Wang YG, et al. Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation. World J Gastroenterol. 2015 Jul 21;21(27):8326-39. [3]. Leoni F, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005 Jan-Dec;11(1-12):1-15.

Butabindide (UCL-1397) 是三肽肽酶II (TPP II)的选择性抑制剂，对 TPP I 和TPP II 的Ki 值分别为 10 μM 和 7 nM。Butabindide 抑制 TPP II 以保护 CCK-8 免于失活。

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P acetate ([D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P acetate (96736-12-8 free base)) 是广谱神经肽反向激动剂和拮抗剂。 ghrelin 受体的强效完全反向激动剂(EC50 = 5.2 nM)；减少组成型生长素释放肽受体信号传导。它也是速激肽、缓激肽、CCK 和铃蟾肽受体的拮抗剂。在体外诱导细胞凋亡并抑制癌细胞生长。

Cholecystokinin Octapeptide, desulfated (CCK Octapeptide, non-sulfated) 是一种由8个氨基酸组成的胆囊收缩素-8。